Product Information
ZORYVE 0.15% CREAM is a brand product labeled by Arcutis Biotherapeutics, Inc., priced at $15.3987 per GM under NDC 80610011560. Its NADAC has been published 98 times since Nov 20, 2024.
FDA first approved this application on Jul 29, 2022.
The High Outlier badge above means this manufacturer's average price in the roflumilast market falls above Q3 + 1.5·IQR across all competing manufacturers. We only apply this flag in markets with four or more competitors. Full definition: glossary → outlier.
Strength
1.5 mg/g
Manufacturer
Arcutis Biotherapeutics, Inc.NDC
80610011560
Classification
Brand
Dosage Form
CREAM
Route
TOPICAL
Effective Date
9/23/2026
Active Ingredients
ROFLUMILASTApproval Type
New Drug (NDA)
FDA Application
NDA215985FDA Approved
7/29/2022
On Market Since
7/9/2024
Pharmacological Classes
Price Statistics
The NADAC for ZORYVE 0.15% CREAM has been published 98 times since Nov 20, 2024, and over the history we have for it it has risen 9.3%. The table below summarizes its recorded NADAC range and movement.
| Current price | $15.3987 per GM |
|---|---|
| All-time high | $15.3996 (Jul 15, 2026) |
| All-time low | $14.0940 (Nov 20, 2024) |
| 52-week high | $15.3996 |
| 52-week low | $14.7870 |
| Median price | $14.7936 |
| Average price | $14.9774 |
| Largest weekly change | +4.0% (Jan 1, 2025) |
| Weeks tracked | 98 |
| Tracking since | Nov 20, 2024 |
Generic Alternatives
No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the roflumilast market page.
Lowest-Cost Alternatives
No alternatives available
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Arcutis Biotherapeutics, Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
roflumilast market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Phosphodiesterase 4 Inhibitor class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of ZORYVE 0.15% CREAM?
The current National Average Drug Acquisition Cost (NADAC) for ZORYVE 0.15% CREAM, manufactured by Arcutis Biotherapeutics, Inc., is $15.3987 per GM (NDC 80610011560), effective Sep 30, 2026.
How has the price of ZORYVE 0.15% CREAM changed over time?
Over the history we have for it, the NADAC for ZORYVE 0.15% CREAM has risen 9.3%. It has been tracked across 98 weekly CMS publications since Nov 20, 2024.
What are the highest and lowest recorded NADAC prices for ZORYVE 0.15% CREAM?
Since Nov 20, 2024, the NADAC for ZORYVE 0.15% CREAM has ranged from a low of $14.0940 (Nov 20, 2024) to a high of $15.3996 (Jul 15, 2026), with a median of $14.7936 per GM.
Are there cheaper alternatives to ZORYVE 0.15% CREAM?
No other NADAC-published product currently shares the active ingredient and strength of ZORYVE 0.15% CREAM in a comparable dosage form, so no direct lower-cost alternative is listed.
Who manufactures ZORYVE 0.15% CREAM?
ZORYVE 0.15% CREAM (NDC 80610011560) is labeled by Arcutis Biotherapeutics, Inc., and CMS classifies it as a brand product.